Immunic Therapeutics
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1200 Avenue of the Americas Ste 200, New...Phone Number
(332) 255-9811Website
www.imux.comRevenue
-Stock Symbol
IMUXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Immunic Therapeutics
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.Explore more
Immunic Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Immunic Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Immunic Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Immunic Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Immunic Therapeutics launches new products
Click to see if Immunic Therapeutics had a recent Job posting/layoffs
Check if Immunic Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Immunic Therapeutics
Earning: See what the market has to say on Immunic Therapeutics recently announced quarterly report
Check out if Immunic Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Immunic Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Immunic Therapeutics
Compare insights from companies similar to Immunic Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Immunic Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Immunic Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Immunic Therapeutics.
Immunic Therapeutics financials insights
Gather financial insights about Immunic Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Share Placement
$60M
2026
Multiple Rounds
$1B
Immunic Therapeutics Tech Stack
A closer look at the technologies used by Immunic Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move, Board of Directors
Executive Move
Executive Moves, Board of Directors
Executive Move
Executive Moves, Board of Directors
Open Position
Seeking Replacement
Immunic Therapeutics News & Media
Immunic director granted options for 25,370 shares | IMUX Insider Trading - Stock Titan
Immunic director Richard Rudick receives 25,370 stock options at a $14.80 exercise price, vesting monthly over one year and expiring July 5, 2036.Immunic (IMUX) director receives grant of 25370 fully vested options - Stock Titan
Immunic director Richard Rudick receives 25,370 fully vested stock options at a $10.90 exercise price, expiring March 27, 2036, under the amended 2019 equity plan.Immunic (NASDAQ: IMUX) director receives 25370 stock options grant
Immunic director Tamar D. Howson receives 25,370 fully vested stock options at a $10.90 exercise price, expiring March 27, 2036, after shareholder approval of a plan amendment.Immunic to Participate in Investor, Industry and Scientific Conferences in June
NEW YORK, June 10, 2026 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor, industry and scientific conferences in June: June...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Immunic Therapeutics
Sign Up For FreeTo access detailed company insights
Immunic is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.... Read More
